CKD患者出院后药物治疗管理:一项随机临床试验
本研究为单盲随机临床试验,纳入141例CKD 3-5期非透析住院患者,比较药师主导的出院后7天内家庭访视药物治疗管理干预与常规护理对90天内急性护理利用的影响。结果显示干预组与常规护理组主要复合终点发生率分别为44%和41%(P=0.72),无显著差异;再入院率均为26%(P=0.95)。结论认为该干预未减少急性护理利用。
要点
- 药师主导的家庭药物治疗管理未降低CKD患者出院后90天内急性护理利用。
- 干预组与常规组再入院率均为26%,无统计学差异。
- 两组在RAS抑制剂使用及血压、血红蛋白、磷、PTH达标方面无差异。
核心结论
- 药师主导的药物治疗管理干预未减少CKD患者出院后的急性护理利用。
研究设计与样本
- 单盲随机临床试验,在华盛顿州斯波坎Providence Health Care进行,纳入141例CKD 3-5期非透析住院患者。
- 干预为药师在出院7天内进行单次家庭访视,包括全面药物审查、药物行动计划和个人药物清单。
主要发现
- 主要复合终点(90天内再入院、急诊和紧急护理访视)干预组32/72(44%),常规组28/69(41%),log rank P=0.72。
- 仅再入院率干预组19/72(26%),常规组18/69(26%),log rank P=0.95。
- 两组在RAS抑制剂使用、血压、血红蛋白、磷或甲状旁腺激素达标方面无组间差异。
临床怎么用
- 对于CKD住院患者,单次药师家庭访视的药物治疗管理策略未显示能减少出院后急性护理利用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: CKD is characterized by remarkably high hospitalization and readmission rates. Our study aim was to test a medication therapy management intervention to reduce subsequent acute care utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The CKD Medication Intervention Trial was a single-blind (investigators), randomized clinical trial conducted at Providence Health Care in Spokane, Washington. Patients with CKD stages 3-5 not treated by dialysis who were hospitalized for acute illness were recruited. The intervention was designed to improve posthospitalization care by medication therapy management. A pharmacist delivered the intervention as a single home visit within 7 days of discharge. The intervention included these fundamental elements: comprehensive medication review, medication action plan, and a personal medication list. The primary outcome was a composite of acute care utilization (hospital readmissions and emergency department and urgent care visits) for 90 days after hospitalization. RESULTS: Baseline characteristics of participants (n=141) included the following: age, 69±11 (mean±SD) years old; women, 48% (67 of 141); diabetes, 56% (79 of 141); hypertension, 83% (117 of 141); eGFR, 41±14 ml/min per 1.73 m2 (serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation); and urine albumin-to-creatinine ratio median, 43 mg/g (interquartile range, 8-528) creatinine. The most common primary diagnoses for hospitalization were the following: cardiovascular events, 36% (51 of 141); infections, 18% (26 of 141); and kidney diseases, 12% (17 of 141). The primary outcome occurred in 32 of 72 (44%) of the medication intervention group and 28 of 69 (41%) of those in usual care (log rank P=0.72). For only hospital readmission, the rate was 19 of 72 (26%) in the medication intervention group and 18 of 69 (26%) in the usual care group (log rank P=0.95). There was no between-group difference in achievement of guideline-based goals for use of renin-angiotensin system inhibition or for BP, hemoglobin, phosphorus, or parathyroid hormone. CONCLUSIONS: Acute care utilization after hospitalization was not reduced by a pharmacist-led medication therapy management intervention at the transition from hospital to home.
引用
- Tuttle KR, Alicic RZ, Short RA, et al. Medication Therapy Management after Hospitalization in CKD: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2018. PMID: 29295829. doi:10.2215/CJN.06790617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。